Pediatric Oncology Clinical Trials
(ALL) Leukemia
Protocol: COG AALL1732
About the study: A Phase 3 Randomized Trial of Inotuzumab Ozogamicin (IND#:133494, NSC#: 772518) for Newly Diagnosed High-Risk B-ALL; Risk-Adapted Post-Induction Therapy for High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and Disseminated B-LLy
Protocol: COG AALL2131
About the study: An International Pilot Study of Chemotherapy and Tyrosine Kinase Inhibitors with Blinatumomab in Patients with Newly-Diagnosed Philadelphia Chromosome-Positive or ABL-Class Philadelphia Chromosome-Like B-Cell Acute Lymphoblastic Leukemia
Protocol: COG AALL2321
About the study: A Phase 2 Study of Blinatumomab in Combination with Chemotherapy for Infants with Newly Diagnosed Acute Lymphoblastic Leukemia with Randomization of KMT2A-Rearranged Patients to Addition of Venetoclax
(ALL) Leukemia Relapse
Protocol: COG AALL1821
About the study: A Phase 2 Study of Blinatumomab (NSC# 765986, IND# 125462) in Combination with Nivolumab (NSC # 748726, IND# 125462), a Checkpoint Inhibitor of PD-1, in B-ALL Patients Aged ? 1 to < 31 Years Old with First Relapse
Protocol: COG AALL2121
About the study: A Phase 2 Study of SNDX-5613 in Combination with Chemotherapy for Patients with Relapsed or Refractory KMT2A-Rearranged Infant Leukemia
(AML) Myeloid Leukemia
Protocol: COG AAML1831
About the study: A Phase 3 Randomized Trial for Patients with de novo AML Comparing Standard Therapy Including Gemtuzumab Ozogamicin (GO) to CPX-351 with GO, and the Addition of the FLT3 Inhibitor Gilteritinib for Patients with FLT3 Mutations
(CNS) Central Nervous System
Protocol: COG ACNS1833
About the study: A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine versus Selumetinib (NSC# 748727, IND# 77782) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) not associated with BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1)
Protocol: COG ACNS2031
About the study: A phase 3 Study of Sodium Thiosulfate for reduction of cisplatin-induced Ototoxicity in children with average risk medulloblastoma and reduced therapy in children with Medulloblastoma with low risk features
Protocol: COG ACNS2321
About the study: A Phase II Trial Evaluating Chemotherapy followed by Response-Based Reduced Radiation Therapy for Patients with Central Nervous System Germinomas
(GCT) Germ Cell
Protocol: COG AGCT1531
About the study: A PHASE 3 STUDY OF ACTIVE SURVEILLANCE FOR LOW RISK AND A RANDOMIZED TRIAL OF CARBOPLATIN VS. CISPLATIN FOR STANDARD RISK PEDIATRIC AND ADULT PATIENTS WITH GERM CELL TUMORS
Protocol: COG AGCT1532
About the study: A randomized phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumors
(HOD) Hodgkins Lymphoma
Protocol: COG AHOD2131
About the study: A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
(LTE) Miscellaneous
Protocol: COG ALTE22C1
About the study: Chronic Health Conditions in Down Syndrome-Associated Acute Leukemia: The Down Syndrome Phenotyping Acute Leukemia Study in Survivors (DS-PALS Survivors)
Protocol: COG ALTE2321
About the study: Walking Juntos: Developing and Testing a Culturally-Tailored Mobile Health and Social MediaPhysical Activity Intervention Among Adolescent and Young Adult Childhood Cancer Survivors
Protocol: COG ALTE2131
About the study: Triptorelin and Protection of Ovarian Reserve in Adolescents and Young Adults with Cancer
Protocol: COG ANHL2121
About the study: A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histiocytosis
Protocol: COG ALTE24C1
About the study: Quality of End-of-Life Care for Children with Cancer: A COG Groupwide Observational Study
(NBL) Neuroblastoma
Protocol: COG ANBL1531
About the study: A PHASE 3 STUDY OF I-METAIODOBENZYLGUANIDINE (I-MIBG) OR CRIZOTINIB ADDED TO INTENSIVE THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA (NBL)
Protocol: COG ANBL2131
About the study: A Phase 3 Study of Dinutuximab Added to Intensive Multimodal Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma
(OST) Osteosarcoma
Protocol: COG AOST2031
About the study: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Protocol: COG AOST2032
About the study: A Feasibility and Randomized Phase 2/3 Study of the VEGFR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
(REN) Renal tumors
Protocol: COG AREN1921
About the study: Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)
Protocol: COG AREN2231
About the study: Risk Adapted Treatment of Unilateral Favorable Histology Wilms Tumors (FHWT)
(RST) Rare Soft Tissue
Protocol: COG ARST2032
About the study: A Prospective Phase 3 Study of Patients with Newly Diagnosed Very Low-risk and Low-risk Fusion Negative Rhabdomyosarcoma
Protocol: COG ARST2531
About the study: A Randomized Phase 3 Study to Compare VAC (Higher Cyclophosphamide Dose and Intensity) versus VAC/VI (Lower Cyclophosphamide Dose and Intensity) Plus Maintenance Therapy in Patients with Newly Diagnosed Intermediate-Risk Rhabdomyosarcoma
Screening/Biology Banking/Registry Studies
Protocol: NCORP DCP-001
About the study: Use of a Clinical Trial Screening Tool to Address Cancer Health Disparities in the NCI Community Oncology Research Program (NCORP)
Protocol: COG APAL2020SC
About the study: Pediatric Acute Leukemia PedAL Screening Trial – Developing new therapies for relapsed leukemias
Protocol: COG APEC14B1 Everychild
About the study: APEC14B1 - The Project: Everychild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study